Fig. 2: Kaplan–Meier estimates of duration of response.
From: Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
a, b, Duration of response per BICR with nivolumab plus chemotherapy versus chemotherapy in patients with PD-L1 CPS ≥ 5 (a) and in all randomized patients (b). c, d, Duration of response with nivolumab plus ipilimumab versus chemotherapy in patients with PD-L1 CPS ≥ 5 (c) and in all randomized patients (d). Number of responders (n) is indicated. Number of randomized patients who had target lesion measurements at baseline per BICR assessment for PD-L1 CPS ≥ 5: NIVO + chemo, n = 378; chemo, n = 390; all randomized: NIVO + chemo, n = 603; chemo, n = 607; PD-L1 CPS ≥ 5: NIVO + IPI, n = 196; chemo, n = 183; and all randomized: NIVO + IPI, n = 333; chemo, n = 299. BICR, blinded independent central review; DOR, duration of response.
